Short answer · Medically reviewed summary · Last updated: 2026-04-07
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age, with an estimated prevalence of approximately 3 to 5 per million women in the general population. While exact global figures remain difficult to determine due to historical underdiagnosis, clinical data suggests that Lymphangioleiomyomatosis is frequently identified in women in their 30s and 40s, though it can present at various stages of adulthood. Is Lymphangioleiomyomatosis considered a rare disease? Yes, Lymphangioleiomyomatosis is classified as a rare disease.
What is the prevalence of Lymphangioleiomyomatosis?
Prevalence of Lymphangioleiomyomatosis: how many people are affected worldwide, differences by sex and region, with sources.
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age, with an estimated prevalence of approximately 3 to 5 per million women in the general population. While exact global figures remain difficult to determine due to historical underdiagnosis, clinical data suggests that Lymphangioleiomyomatosis is frequently identified in women in their 30s and 40s, though it can present at various stages of adulthood.
Is Lymphangioleiomyomatosis considered a rare disease?
Yes, Lymphangioleiomyomatosis is classified as a rare disease. Because it primarily targets women and often mimics more common respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD), it is historically underdiagnosed. Researchers estimate the prevalence to be roughly 3 to 5 per million women, though some expert centers believe the actual number of people living with Lymphangioleiomyomatosis may be higher due to improved high-resolution computed tomography (HRCT) scanning and increased clinical awareness.
Who is most at risk for developing Lymphangioleiomyomatosis?
Lymphangioleiomyomatosis almost exclusively affects women. While there have been rare reports of the disease in males, these cases are typically associated with tuberous sclerosis complex (TSC). The age of onset for Lymphangioleiomyomatosis is most commonly between 20 and 40 years old, coinciding with the reproductive years, which has led researchers to investigate the role of estrogen in disease progression. There is no significant evidence of geographic or ethnic clusters, suggesting that Lymphangioleiomyomatosis occurs globally across all populations.
Why is accurate prevalence data for Lymphangioleiomyomatosis challenging?
Obtaining precise epidemiological data for Lymphangioleiomyomatosis remains a complex task for the medical community for several reasons:
- Diagnostic Delay: Many patients experience a "diagnostic odyssey," where symptoms are initially attributed to other lung conditions, leading to significant delays before an accurate diagnosis of Lymphangioleiomyomatosis is confirmed.
- Variability in Presentation: The disease can range from mild, slow-progressing cases to more aggressive forms, meaning some individuals may remain undiagnosed for years.
- Reporting Limitations: Because it is a rare disease, there is no universal global registry, making it difficult to capture every case occurring worldwide.
How does the DiseaseMaps community contribute to our understanding?
Real-world data provides a vital perspective that clinical studies sometimes miss. Currently, 9 people with Lymphangioleiomyomatosis have joined the DiseaseMaps.org community to share their personal experiences. By mapping these individual journeys, our community helps highlight the human element of Lymphangioleiomyomatosis, providing peer support and collective insights that complement the formal epidemiological statistics provided by international health organizations.
Next steps
- Consult a pulmonologist or a specialist at a center of excellence that focuses on interstitial lung diseases (ILD) or rare cystic lung diseases.
- Request a referral for genetic counseling if you have a family history of tuberous sclerosis complex.
- Join a patient support organization, such as The LAM Foundation, to access educational resources and connect with others navigating a Lymphangioleiomyomatosis diagnosis.
- Register with patient-led platforms like DiseaseMaps.org to share your experiences and stay updated on emerging clinical research.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- Orphanet: Lymphangioleiomyomatosis (ORPHA:517)
- NIH Genetic and Rare Diseases Information Center (GARD): Lymphangioleiomyomatosis
- The LAM Foundation: Understanding LAM and Prevalence Data
- PubMed/National Library of Medicine: Epidemiology and clinical features of sporadic lymphangioleiomyomatosis
